Press
A brief, on-record space for journalists reporting on cross-border specialty pharmacy, named-patient access, and the regulatory landscape around US-sourced medicines delivered abroad.
Company fact sheet
Reserve Meds is a brand operated by Altima Care, a US-licensed specialty wholesaler. The service coordinates named-patient and personal-import access to US-sourced specialty medicines for patients in the United Arab Emirates, Saudi Arabia, India, Pakistan, Egypt, and a further set of jurisdictions where the named-patient pathway is open for the indication in question. The business was founded by a practising physician with two decades in US specialty distribution and a prior healthcare exit; the full leadership bio is on the About page. The service is cash-pay, concierge-tier, and operates on DSCSA-compliant sourcing through licensed US specialty wholesalers.
Press contacts
Press enquiries should be directed to [email protected]. For time-sensitive requests, please include the publication, the deadline, and a short description of the angle; we aim to respond within one business day and, where appropriate, to offer a named executive or the pharmacist-in-charge on the record. General media queries that are not tied to a specific story can be sent to the same address and will be routed accordingly.
What we will comment on
We are prepared to speak, on the record, on a defined set of subjects. The first is named-patient access as a regulatory mechanism: how it works in the United States as a source country, how it works in the principal destination countries we serve, and how the pathway differs from parallel import, gray-market sourcing, and compassionate-use programmes. The second is cross-border specialty coordination: the practical logistics of cold-chain handling, chain-of-custody documentation, and physician-to-pharmacist communication across jurisdictions. The third is DSCSA-compliant sourcing: the traceability obligations the US statute imposes, and how those obligations carry forward into the destination country. The fourth is the regulatory-pathway-agnostic posture we take: we do not advocate for any particular pathway or jurisdictional approach and can describe the trade-offs among them.
What we do not comment on
There are three categories on which we decline to comment, consistently, as a matter of house rule. We do not comment on individual patient cases, including cases where the patient or the family has chosen to speak publicly. We do not comment on pending regulatory matters involving our business or our vendors; once a matter is resolved and the regulator has published its decision, we can address the outcome. And we do not comment on third-party pricing, manufacturer commercial practices, or the pricing decisions of other distributors; our knowledge of those matters is commercial and we do not consider it appropriate to share on record.
Availability of executives and clinicians
The founder-CEO is available for interviews on the subjects above, in English, with reasonable notice. The pharmacist-in-charge at Altima Care is available for technical interviews on sourcing, dispensing, and cold-chain handling. For questions on destination-country regulatory landscapes we can, with appropriate notice, introduce local clinicians or regulatory practitioners on background. We do not provide on-camera patient interviews and we do not facilitate contact with families we have served.
About Reserve Meds — boilerplate for reporter use
Reserve Meds is a cross-border named-patient-program coordinator that arranges access to US-sourced medicines for seriously ill patients in the United Arab Emirates, Saudi Arabia, India, Pakistan, Egypt, and further destinations where the named-patient pathway is available. The service is operated by Altima Care, a US-licensed specialty wholesaler, with prescription review conducted under US-licensed specialty pharmacy workflow. Reserve Meds sources every therapy through DSCSA-compliant US specialty wholesalers, coordinates import documentation in the destination country under published regulatory pathways, and ships under validated cold-chain handling to the treating physician or hospital pharmacy. The company is headquartered in the United States and serves patients, physicians, and institutions on a cash-pay basis. More at reservemeds.com.
Reviewed 2026-04-22 by Reserve Meds's AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.